Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Herentals – page 74

2 092 clinical trials in Herentals, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Herentals at a glance
2 092
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 092 trials in Herentals

Open in trial search

Acquired ATTR amyloidosis

Not yet recruiting

A Study of Acoramidis for Long-Term Safety in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis Hydrochloride
  • Sponsor:Eidos Therapeutics Inc.

Non-small cell lung cancer

Not yet recruiting

Study of zipalertinib plus chemotherapy versus placebo plus chemotherapy in patients with stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after surgery

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Taiho Oncology Inc.

Sarcopenia

Not yet recruiting

Evaluation of BIO-101 versus placebo for treating severe sarcopenia in elderly patients with reduced mobility

Investigational
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:20-HYDROXYECDYSONE
  • Sponsor:Biophytis

Systemic lupus erythematosus+1

Not yet recruiting

Study of CC-97540 CD19-targeted CAR T cells in patients with systemic lupus erythematosus who did not respond to previous immunosuppressive treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Bronchiectasis

Not yet recruiting

Study of Nebulized Human Normal Immunoglobulin (CSL787) for Adults with Non-cystic Fibrosis Bronchiectasis to Find Best Dose and Test Safety

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:CSL Behring LLC

Fallopian tube cancer+1

Not yet recruiting

Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Torl Biotherapeutics LLC

Medulloblastoma

Not yet recruiting

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Cardiac failure+5

Not yet recruiting

Study of cardiac atrial stem cells injected into heart muscle for treating advanced heart failure in patients with prior heart attack and reduced heart function

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:CASCS
  • Sponsor:CASC8

Colitis ulcerative

Not yet recruiting

Study on the Safety and Effectiveness of OD-07656 and Vedolizumab for Patients with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Vedolizumab
  • Sponsor:Odyssey Therapeutics Inc.

Gastrointestinal disorder

Not yet recruiting

Study on the Safety and Effects of Orziloben (NST-6179) for Patients with Intestinal Failure-Associated Liver Disease

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Orziloben
  • Sponsor:NorthSea Therapeutics B.V.

COVID-19

Not yet recruiting

Study on COVID-19 Immunity in Immunocompromised Adults Using Raxtozinameran and Bretovameran in Belgium

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Bretovameran
  • Sponsor:Sciensano

Autism spectrum disorder

Not yet recruiting

Study on Improving Social Interaction in Children with Autism Using Oxytocin Nasal Spray and Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · Healthy volunteers
  • Substances:Oxytocin
  • Sponsor:UZ Leuven

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Herentals

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on follicular lymphoma and diffuse large B-cell lymphoma, evaluating novel therapeutic approaches against traditional treatments.

  • Comparative treatment studies
  • Safety and efficacy evaluation
  • Advanced lymphoma therapies

These trials aim to improve treatment outcomes for patients with various forms of lymphoma through targeted therapies.

02 Multiple Myeloma Research

Groundbreaking studies exploring early intervention in monoclonal gammopathy and smoldering multiple myeloma conditions.

  • Plasma cell disorders
  • Early disease intervention
  • Novel therapeutic approaches

Research focused on preventing progression to active multiple myeloma through innovative treatments.

03 Rheumatology Studies

Investigation of treatment strategies for rheumatoid arthritis, comparing conventional approaches with accelerated biological therapy access.

  • Early RA intervention
  • Long-term effectiveness
  • Treatment optimization

Comprehensive evaluation of various treatment approaches for better disease management outcomes.

04 Gastroenterology Research

Studies examining optimal approaches for PPI deprescription in patients with various gastrointestinal conditions including functional dyspepsia and reflux.

  • Medication optimization
  • Alternative treatment strategies
  • Patient-centered approaches

Focused on developing effective strategies for reducing long-term PPI use while maintaining symptom control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.